This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Amyris, Inc. Sued By Investor

Stocks in this article: AMRS

SAN DIEGO & EMERYVILLE, Calif., May 21, 2013 /PRNewswire/ --  Shareholder rights attorneys at Robbins Arroyo LLP announce that a purchaser of Amyris, Inc. (NASDAQ: AMRS) securities has filed a complaint in the U.S. District Court for the Northern District of California.  The complaint alleges that Amyris and certain of its officers and directors violated the Securities Exchange Act of 1934 between April 29, 2011 and February 8, 2012 (the "Class Period").  Amyris is a renewable products company that produces various alternatives to a range of petroleum-sourced products for the specialty chemical and transportation fuel markets worldwide.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Amyris Is Accused of Making False and Misleading Statements Regarding Its Ability to Sustain Commercial Production of Biofene

The complaint alleges that during the Class Period, Amyris and its President and CEO issued a series of materially false and misleading statements concerning the true nature of the company's operations and prospects.  On April 29, 2011, according to the complaint, the company announced that it had designed a facility capable of the sustained commercial production of Biofene. Then on May 5, 2011, the company indicated that it expected to produce 6 million to 9 million liters of Biofene in 2011 and an additional 40 million to 50 million liters in 2012.   According to the complaint, those statements were false and misleading because the scalability of the company's production to commercial levels was unsuccessful, and the company's representations regarding their ability to achieve the expected production capacities had no basis in fact.



Amyris Stock Price Falls Dramatically on the Announcement of Reduced Production Capabilities

On November 1, 2011, Amyris reported that it lacked the ability to produce the volume of Biofene that it previously projected, and was reducing its production projections dramatically.  On this news, the company's stock price dropped 20% to close at $15.47 per share on November 2, 2011.  On February 9, 2012, the company announced that it was having additional problems producing Biofene at commercially viable levels and that the previously estimated 40 million to 50 million liters of Biofene for 2012 were being scrapped.  Moreover, the company reported that it was no longer anticipating positive cash flow from operations in 2012.  As a result of this news, the company's stock price dropped 28%, or $2.74 per share, to close at $6.99 per share.

If you purchased or otherwise acquired Amyris stock during the Class Period and wish to serve as lead plaintiff, you must act no later than July 15, 2013.  To discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website. 

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/amyris-inc/

Attorney Advertising. Past results do not guarantee a similar outcome.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,607.24 -65.36 -0.37%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs